All Boards >> Irritable Bowel Syndrome Research Library


Reged: 12/09/02
Posts: 7687
Loc: Seattle, WA
Editorial - Antibiotic Rifaximin (Xifaxan) Therapy for the Irritable Bowel Syndrome
01/07/11 03:01 PM

Antibiotic Therapy for the Irritable Bowel Syndrome

Jan Tack, M.D., Ph.D.

N Engl J Med 2011; 364:81-82January 6, 2011


The irritable bowel syndrome (IBS) is one of the most common conditions seen in clinical practice. The number of effective pharmacologic agents for IBS is limited, and therapeutic innovation is hampered by a lack of complete understanding of the pathophysiology of the syndrome, which is probably heterogeneous.1 Alterations in the bacterial flora are increasingly considered to be a relevant pathogenetic factor.2 Consequently, probiotics are being studied as treatment for IBS, but the magnitude of improvement in symptoms with probiotics is limited.2 Some studies have suggested that there are beneficial effects with poorly absorbed antibiotics, but the results of the studies have been questioned because of issues with patient selection, the choice of end point, and the statistical analysis, and, most of all, because lactulose breath test results were interpreted as indicative of small-intestine bacterial overgrowth.3-6

In this issue of the Journal, Pimentel et al. report the results of two identically designed, large, double-blind, placebo-controlled trials (TARGET 1 and TARGET 2) of rifaximin, a poorly absorbed antibiotic, in patients with IBS without constipation.7 A total of 1260 patients were randomly assigned to receive rifaximin, at a dose of 550 mg three times daily, or placebo for 2 weeks, followed by a 10-week posttreatment follow-up period. The primary end point was the proportion of patients who reported adequate relief of IBS symptoms, as assessed by responses (yes or no) to a question about relief of symptoms that was asked weekly during the first 4 weeks after treatment. The key secondary end point was the proportion of patients reporting adequate relief of bloating during the same period.

In both studies, patients consistently met the criteria for relief of global IBS symptoms and IBS-related bloating. In the rifaximin groups, as compared with the placebo groups, a significantly higher proportion of patients reported adequate relief of IBS symptoms (41% vs. 32% in the two trials combined, P<0.001) or bloating (40% vs. 30%, P<0.001) for at least 2 of the first 4 weeks. Similarly significant results were obtained in an analysis of relief of symptoms during the 10-week period after the end of the double-blind treatment phase.

These large, high-quality, multicenter studies confirm that, as a group, patients who have IBS without constipation have a significantly better response to rifaximin than to placebo. Rifaximin is a poorly absorbed antibiotic with broad-spectrum activity against gram-negative bacteria, gram-positive bacteria, and anaerobes, including Clostridium difficile. It has been extensively used in the treatment and prevention of travelers' diarrhea, for which it has shown a favorable side-effect and safety profile, with low risk for the development of resistance.8

The TARGET studies have some attractive findings. First, the sustained benefit over at least 10 weeks, after a short treatment course, is appealing. Second, the beneficial effects of rifaximin include its effects on bloating, which is one of the most challenging symptoms of IBS. Third, the similarity of the results in both studies confirms the reproducibility of the therapeutic effect. On the other hand, the therapeutic gain, with the rates of response to treatment (i.e., adequate relief) ranging between 9 and 12% more with rifaximin than with placebo, is in the lower spectrum of what is considered to be clinically relevant.9 Although it is clear that not all patients have a response with rifaximin, the available data suggest that a subgroup of patients may have a substantial response.5,7 It is unclear whether this group can be identified by demographic characteristics, symptoms, or results of lactulose breath testing. Most important, IBS is a chronic disorder, and although the therapeutic effect persists after the 2-week treatment period, the response over time suggests that there is some loss of efficacy, as compared with placebo, with respect to certain symptoms toward the end of the 10-week follow-up period. It is unknown whether patients would have a favorable response again with retreatment.

The mechanism underlying the beneficial effect of rifaximin with respect to symptoms of IBS is a matter of controversy. Initial studies of poorly absorbed antibiotics for the treatment of patients with IBS were based on the hypothesis that a large proportion of these patients had small-intestine bacterial overgrowth, a disorder characterized by the presence of abnormally high numbers of bacteria in the small intestine.7 Initial studies reported the presence of small-intestine bacterial overgrowth in up to 80% of patients, on the basis of a rapid rise in breath hydrogen during lactulose breath testing. However, this test is prone to false positive results, and several other investigators failed to reproduce these high incidences.10 When the standard method of jejunal aspiration and bacterial culturing was used, small-intestine bacterial overgrowth was found in only 4% of patients with IBS.10 More recently, it was suggested that the use of proton-pump inhibitors conferred a predisposition to enhanced bacterial colonization of the small intestine.10 Most studies assessing poorly absorbed antibiotics in the treatment of patients with IBS, including the present study, do not report or adjust for the concomitant use of proton-pump inhibitors, so this remains an area of controversy. The most likely mode of action of rifaximin is a reduction in overall bacterial load, especially in the large bowel.8 This may lead to decreased bacterial fermentation and less bloating, possibly in combination with decreased secretion of bacterial products or host responses to bacterial products that contribute to the generation of symptoms.

Neither rifaximin nor any other antibiotic has been approved for the treatment of IBS, and the Food and Drug Administration is currently reviewing the new-drug application for rifaximin for the treatment of patients who have IBS without constipation and IBS-related bloating. With three studies confirming the efficacy of the drug after a short-term regimen and a relatively short follow-up period,5,7 rifaximin has the potential to provide a welcome addition to the limited armamentarium of agents that are available to treat IBS. Moreover, rifaximin had a favorable safety profile in these studies, with no treatment-associated major adverse events and no cases of C. difficile colitis. At the current stage of knowledge, however, clinicians should proceed with caution. IBS is a chronic condition, and some regulatory authorities recommend that studies be conducted that will address the efficacy of rifaximin when it is used for continued or intermittent treatment of IBS (see, and this seems to be even more appropriate in the case of antibiotic therapy that may have a risk of inducing resistance over time. Furthermore, taking into account the high prevalence of IBS in the general population, the effect that larger-scale use of poorly absorbed antibiotics may have on antibiotic-resistance profiles should be taken into account.6 Studies aimed at better identifying the patients with IBS who may have a response to rifaximin and, especially, studies that will assess the longer-term effect of rifaximin treatment are eagerly awaited. Until this information becomes available, it seems prudent to restrict the use of nonabsorbable antibiotics to patients in whom small-intestine bacterial overgrowth has been confirmed, or to single-treatment cycles in patients who have IBS without constipation and who have not had a response to currently available symptom-directed therapies.1

Disclosure forms provided by the author are available with the full text of this article at
Source Information

From the Department of Pathophysiology, Translational Research Center for Gastrointestinal Disorders, University of Leuven, Leuven, Belgium.

Heather is the Administrator of the IBS Message Boards. Shes the author of Eating for IBS and The First Year: IBS, and the CEO of Heather's Tummy Care. Join her IBS Newsletter. Meet Heather on Facebook!

Post Extras Print Post Remind Me! Notify Moderator

Entire thread
Subject Posted by Posted on
* Pharmaceutical HeatherAdministrator 07/14/03 01:50 PM
. * Long-term cannabis use increases risk for IBS HeatherAdministrator 10/19/17 04:04 PM
. * FDA approves new drug for chronic constipation HeatherAdministrator 01/26/17 03:05 PM
. * Mixed Opioid Agent Adds to Growing List of Therapies for IBS-D HeatherAdministrator 01/27/16 02:48 PM
. * Low-dose naltreoxone for the treatment of irritable bowel syndrome HeatherAdministrator 01/26/16 01:20 PM
. * Amitiza benefited patients with chronic idiopathic constipation HeatherAdministrator 02/10/15 04:15 PM
. * Medical Marijuana for Digestive Disorders: High Time to Prescribe? HeatherAdministrator 09/17/14 02:08 PM
. * Antibiotics Early in Life May Boost Obesity Risk HeatherAdministrator 08/18/14 03:13 PM
. * Antidepressants, psychological therapies effectively treated IBS HeatherAdministrator 07/15/14 02:49 PM
. * Proton pump inhibitor (acid reflux drugs) may cause heart disease HeatherAdministrator 09/23/13 03:22 PM
. * Older drugs are better than new ones HeatherAdministrator 06/13/13 02:00 PM
. * On Anti-Depressants? Some Raise Risk of C. Diff Infection HeatherAdministrator 05/13/13 05:51 PM
. * Heartburn drugs, NSAID painkillers use linked to IBS symptoms HeatherAdministrator 03/18/13 01:24 PM
. * FDA approves Linzess to treat certain cases of irritable bowel syndrome and constipation HeatherAdministrator 08/31/12 11:25 AM
. * 3-month FDA delay for potential IBS drug linaclotide HeatherAdministrator 04/23/12 01:45 PM
. * Latest FDA watch list includes GI drugs HeatherAdministrator 04/23/12 01:42 PM
. * Antibiotics that reduce gut bacteria linked to obesity HeatherAdministrator 05/06/11 12:25 PM
. * Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases HeatherAdministrator 02/10/11 10:23 AM
. * Antacids increase risk of pneumonia HeatherAdministrator 01/14/11 04:35 PM
. * Editorial - Antibiotic Rifaximin (Xifaxan) Therapy for the Irritable Bowel Syndrome HeatherAdministrator 01/07/11 03:01 PM
. * Antiobiotic Rifaximin (Xifaxan) for Patients with Irritable Bowel Syndrome without Constipation HeatherAdministrator 01/07/11 02:59 PM
. * Proton Pump Inhibitor Drugs Tied to 80% Increase in Clostridium difficile Risk HeatherAdministrator 11/10/10 11:29 AM
. * Phase 3 clinical trials of linaclotide for IBS constipation HeatherAdministrator 10/13/10 02:44 PM
. * An over-the-counter drug for constipation offers superior symptom relief compared with a commonly used prescription agent HeatherAdministrator 07/16/10 03:17 PM
. * Benefit/risk ratio of Renzapride not sufficient to warrant further study in IBS-C HeatherAdministrator 04/07/10 01:32 PM
. * Adverse effects of drugs on small intestine and colon HeatherAdministrator 03/16/10 11:23 AM
. * Children's Belly Aches Don't Disappear With Antidepressant HeatherAdministrator 03/11/10 01:14 PM
. * Survey: Marijuana Use In Patients With IBS HeatherAdministrator 01/12/10 03:17 PM
. * FDA Approves Amitiza for IBS-C HeatherAdministrator 05/23/08 10:59 AM
. * Zelnorm no longer available except for emergency use HeatherAdministrator 04/11/08 12:05 PM
. * Clinical trial: phase 2 trial of lubiprostone for irritable bowel syndrome with constipation. HeatherAdministrator 02/15/08 11:20 AM
. * Role of Antibiotics vs Conventional Pharmacotherapy in Treating Symptoms of Irritable Bowel Syndrome HeatherAdministrator 01/03/08 04:45 PM
. * FDA permits the restricted use of Zelnorm HeatherAdministrator 08/09/07 11:41 AM
. * Antidepressant Therapy (Imipramine and Citalopram) for Irritable Bowel Syndrome HeatherAdministrator 06/20/07 01:56 PM
. * Neuromuscular Dysfunction and IBS: Clinical Implications for Drug Use HeatherAdministrator 02/04/07 04:30 PM
. * Enteric Bacteria and IBS HeatherAdministrator 11/26/06 02:51 PM
. * Rifaximin vs Placebo in Reducing Symptoms in Adults With IBS HeatherAdministrator 11/26/06 02:39 PM
. * Antibiotic Rifaximin Appears Safe and Effective for Irritable Bowel Syndrome HeatherAdministrator 10/26/06 10:29 AM
. * Citalopram (Celexa) Improves Symptoms of Irritable Bowel Syndrome HeatherAdministrator 10/14/06 12:57 PM
. * Marijuana eases chronic pain HeatherAdministrator 07/17/06 11:49 AM
. * Doctors group launches war on drug ads HeatherAdministrator 07/17/06 11:17 AM
. * New IBS drug in development in Japan HeatherAdministrator 07/05/06 05:13 PM
. * Marijuana and the gastrointestinal tract HeatherAdministrator 06/12/06 03:38 PM
. * Zelnorm Rejected Again in Europe HeatherAdministrator 04/02/06 03:25 PM
. * Antidepressants for IBS HeatherAdministrator 03/16/06 12:31 PM
. * Takeda Laxative Wins U.S. Approval for Adults HeatherAdministrator 02/18/06 01:36 PM
. * Cilansetron: ; Solvay Pharmaceuticals suspends registration activites in the U.S., HeatherAdministrator 01/18/06 04:15 PM
. * Hearburn Drugs Cause Diarrhea HeatherAdministrator 01/08/06 05:10 PM
. * Zelnorm fails to win EU panel backing HeatherAdministrator 12/21/05 11:25 AM
. * Non-steroidal anti-inflammatory drugs and gastrointestinal damage HeatherAdministrator 12/08/05 12:51 PM
. * Octreotide May Be Effective in Treatment of Nonconstipated IBS HeatherAdministrator 12/08/05 12:31 PM
. * Lack of Lasting Effectiveness of Miralax Laxative Treatment of Constipation. HeatherAdministrator 08/07/05 04:18 PM
. * Acute Hepatitis Associated With Lotronex HeatherAdministrator 07/24/05 02:37 PM
. * FDA revisions to safety labeling for Lotronex (alosetron ) HeatherAdministrator 05/22/05 06:46 PM
. * Clinical pharmacology of new motility promoting agents HeatherAdministrator 05/22/05 06:33 PM
. * Rationale for Using Serotonergic Agents to Treat Irritable Bowel Syndrome HeatherAdministrator 05/08/05 06:21 PM
. * Zelnorm Associated With Rare Cases of Severe Diarrhea, Ischemic Colitis HeatherAdministrator 04/24/05 03:48 PM
. * Clinical Response to Tricyclic Antidepressants in Functional Bowel Disorders not Related to Dosage HeatherAdministrator 03/28/05 01:32 PM
. * Efficacy and Safety of Alosetron in Men with Diarrhea-Predominant IBS HeatherAdministrator 02/19/05 05:56 PM
. * Irritable Bowel Syndrome Medications Side Effects Survey HeatherAdministrator 11/09/04 02:04 PM
. * On the Relationship Between Colon Ischemia, Irritable Bowel Syndrome, and Serotonergic Therapy of Irritable Bowel Syndrome HeatherAdministrator 10/24/04 07:10 PM
. * New Risk Information on Zelnorm for IBS for Women HeatherAdministrator 07/11/04 02:18 PM
. * The Relationship among Previous Antimicrobial Use and H. Pylori Infections HeatherAdministrator 06/27/04 01:33 PM
. * Therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome HeatherAdministrator 06/04/04 03:54 PM
. * Pharmaceutical companies funding a number of studies into IBS in the UK HeatherAdministrator 05/25/04 12:00 PM
. * Irritable bowel syndrome helped by Paroxetine, a drug for depression HeatherAdministrator 05/10/04 02:15 PM
. * Fears cause low sales of Lotronex HeatherAdministrator 05/10/04 01:46 PM
. * Zelnorm Warning Issued by FDA HeatherAdministrator 05/10/04 01:01 PM
. * Renzapride Improves Symptoms in Constipation-Predominant Irritable Bowel Syndrome HeatherAdministrator 12/01/03 06:14 PM
. * Clinical Trial Guidelines for Pharmacological Treatment of IBS - Pharmacological Options HeatherAdministrator 12/01/03 05:55 PM
. * SOLVAY presses ahead with cilansetron, a new IBS drug HeatherAdministrator 11/18/03 03:43 PM
. * Measuring Treatment Effects in IBS Trials HeatherAdministrator 10/20/03 03:30 PM
. * FDA Orders Novartis To Pull Zelnorm Ads HeatherAdministrator 10/07/03 11:25 PM
. * Step-down dosage of PPI drugs for hearburn HeatherAdministrator 09/30/03 01:26 PM
. * Evaluation of drug treatment in irritable bowel syndrome HeatherAdministrator 09/30/03 12:52 PM
. * Pain Relievers and Intestinal Disorders HeatherAdministrator 09/16/03 04:20 PM
. * Hypersensitivity and hyperreactivity in IBS: opportunity for drug discovery HeatherAdministrator 07/18/03 12:39 PM
. * Antidepressants in the Treatment of IBS and Other Functional GI Disorders HeatherAdministrator 07/18/03 12:20 PM
. * Use of Antidepressants in the Treatment of IBS? HeatherAdministrator 07/14/03 03:58 PM
. * Combined use of SSRIs and NSAIDs increases the risk of GI adverse effects HeatherAdministrator 07/14/03 03:15 PM

Extra information
0 registered and 15 anonymous users are browsing this forum.

Moderator:  Heather 

You cannot post until you login
You cannot reply until you login
HTML is enabled
UBBCode is enabled

Thread views: 348848

Jump to

| Privacy statement Help for IBS Home

UBB.threads™ 6.2

Shop For IBS Here!